Adoption and Diffusion of Evidence-Based Addiction Medications in Substance Abuse Treatment

Adoption and Diffusion of Evidence-Based Addiction Medications in Substance Abuse Treatment
复制标题

DOI:
10.1111/1475-6773.12093
复制
发表时间:
2014-02-01
影响因子:
3.4
通讯作者:
Cummings, Grant R.
Cummings, Grant R.
中科院分区:
医学3区
文献类型:
--
作者:
Heinrich, Carolyn J.;Cummings, Grant R.

文献摘要

被引文献

相似文献

目的研究设施和国家层面的因素在治疗设施的采用和药物制剂在成瘾治疗中的扩散中的作用。数据来源二级数据来自国家药物滥用治疗服务调查(N-SSATS),药物滥用和精神卫生服务管理局(SAMHSA),医疗保险和医疗补助服务中心,酒精政策信息系统,研究设计我们估计有序logit和多项logit模型,以检查状态和治疗设施特征与三种药物制剂在4年内的采用和扩散的关系,每种药物处于不同的采用或扩散阶段。数据收集N-SSATS数据与设施代码,直接从SAMHSA获得,由国家标识符链接到其他公开可用的,次要的data.Principal FindingsThe分析证实了意识和暴露于他人的采用行为,传播有关创新的可行性和有效性,地理集群,在使机构在成瘾治疗中采用和继续使用药物疗法合法化方面,存在政策和行政杠杆,以增加制药技术的可用性,药物滥用治疗机构继续使用这些药物。
ObjectiveTo examine the roles of facility‐ and state‐level factors in treatment facilities' adoption and diffusion of pharmaceutical agents used in addiction treatment.Data SourcesSecondary data from the National Survey of Substance Abuse Treatment Services (N‐SSATS), Substance Abuse and Mental Health Services Administration (SAMHSA), Centers for Medicare and Medicaid Services, Alcohol Policy Information System, and Kaiser Family Foundation.Study DesignWe estimate ordered logit and multinomial logit models to examine the relationship of state and treatment facility characteristics to the adoption and diffusion of three pharmaceutical agents over 4 years when each was at a different stage of adoption or diffusion.Data CollectionN‐SSATS data with facility codes, obtained directly from SAMHSA, were linked by state identifiers to the other publicly available, secondary data.Principal FindingsThe analysis confirms the importance of awareness and exposure to the adoption behavior of others, dissemination of information about the feasibility and effectiveness of innovations, geographical clustering, and licensing and accreditation in legitimizing facilities' adoption and continued use of pharmacotherapies in addiction treatment.ConclusionsPolicy and administrative levers exist to increase the availability of pharmaceutical technologies and their continued use by substance abuse treatment facilities.